MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.540
-0.050
-3.14%
After Hours: 1.610 +0.07 +4.55% 19:34 12/05 EST
OPEN
1.590
PREV CLOSE
1.590
HIGH
1.600
LOW
1.530
VOLUME
2.20M
TURNOVER
--
52 WEEK HIGH
4.079
52 WEEK LOW
1.445
MARKET CAP
408.66M
P/E (TTM)
-20.2632
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS)
TipRanks · 2d ago
Akebia Therapeutics Price Target Maintained With a $5.00/Share by BTIG
Dow Jones · 3d ago
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
Benzinga · 3d ago
Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
Benzinga · 3d ago
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
TipRanks · 3d ago
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?
Barchart · 3d ago
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 4d ago
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.